PMV Pharmaceuticals, Inc. - 8-K Filing
PMV Pharmaceuticals held its virtual 2026 Annual Meeting of Stockholders on June 4, 2026. Shareholders elected David H. Mack and Laurie Stelzer as Class III Directors with vote totals of 15,693,907 for Mack (vs. 6,248,461 withheld) and 11,261,111 for Stelzer (vs. 10,681,257 withheld). They also approved executive compensation with 15,015,578 votes in favor and ratified Ernst & Young LLP as the independent auditor with 28,379,108 votes supporting. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $PMVP